AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (275.5 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Commentary | Open Access

Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

Xiujing Feng, Yujun Hao, Zhenghe Wang,( )
Department of Genetics and Genome Sciences and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations.

References

1

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
Crossref Google Scholar
2

Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
Crossref Google Scholar
3

Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495-501.
Crossref Google Scholar
4

Hao Y, Samuels Y, Li Q, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 2016;7:11971.
Crossref Google Scholar
5

Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101-105.
Crossref Google Scholar
6

Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature. 2015;518:240-244.
Crossref Google Scholar
7

Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27:533-546.
Crossref Google Scholar
8

Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678-3684.
Crossref Google Scholar
9

Gross MI, Demo SD, Dennison JB, et al. Antitumor Activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890-901.
Crossref Google Scholar
Genes & Diseases
Volume 3 Issue 4,
December 2016
Pages 241-243
DOI: 10.1016/j.gendis.2016.09.001
Cite this article:
Feng X, Hao Y, Wang Z. Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. Genes & Diseases, 2016, 3(4): 241-243. https://doi.org/10.1016/j.gendis.2016.09.001

210

Views

2

Downloads

13

Crossref

N/A

Web of Science

14

Scopus

0

CSCD

Altmetrics
Received: 26 August 2016
Accepted: 03 September 2016
Published: 10 September 2016
© 2016, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return